A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 04 Mar 2019 Planned End Date changed from 20 Jun 2020 to 23 Mar 2021.
- 04 Mar 2019 Planned primary completion date changed from 10 Jan 2019 to 1 Dec 2020.
- 22 Oct 2018 Planned End Date changed from 20 Mar 2020 to 20 Jun 2020.